Application of hydrogen nano bubble water in preparation of medicine for preventing and treating pneumoconiosis

Abstract

The invention relates to the technical field of biomedicine, in particular to application of hydrogen nanobubble water in preparation of medicine for preventing and treating pneumoconiosis. The invention provides application of hydrogen nano bubble water in preparation of a medicine for preventing and treating pneumoconiosis. The research on the application of the hydrogen nanobubble water to pneumoconiosis has important clinical significance on exploring low-toxicity and high-efficiency gas medicines or drinks for preventing and treating pneumoconiosis.

Description

Technical Field

[0001] The present invention relates to the field of biomedical technology, and in particular to application of hydrogen nano bubble water in the preparation of medicines for preventing and treating pneumoconiosis. Background Art

[0002] Pneumoconiosis is the most serious occupational disease, primarily caused by long-term inhalation of industrial dust, which leads to irreversible lung fibrosis. The disease is prevalent in industries such as coal mining, metallurgy, building materials, and machinery manufacturing, with most patients being frontline workers, particularly migrant workers. According to statistics, pneumoconiosis cases account for approximately 90% of all occupational diseases. Silicosis, the most common pathological form of occupational pneumoconiosis, is irreversible interstitial lung damage caused by long-term exposure to high concentrations of crystalline silica dust. There is currently a lack of internationally recognized effective medications for the treatment of pneumoconiosis. Clinically used drugs such as silicone and hydroxypiperaquine phosphate have yet to achieve widespread global acceptance. To address this disease, the clinical application of anti-fibrotic drugs such as nintedanib is still in the exploratory stage. Current treatment strategies for pneumoconiosis focus on relieving symptoms, delaying disease progression, and improving patients' quality of life. For patients with advanced pneumoconiosis, established pulmonary fibrosis is irreversible, making lung transplantation the only viable treatment option. However, this therapy faces practical challenges such as a shortage of donors, high surgical costs, immune rejection, and poor quality of life after surgery. Therefore, current treatment options for pneumoconiosis remain insufficient, and the development of targeted therapeutic drugs is key to overcoming this medical challenge.

[0003] Hydrogen (H2) is a colorless and odorless gaseous signaling molecule. Its small size, strong penetrating power and high safety make it a hot topic in biomedical research. As a selective antioxidant, hydrogen can efficiently scavenge harmful free radicals (such as hydroxyl radicals and peroxynitrites), reduce oxidative stress damage, and does not affect important reactive oxygen signaling molecules in the body. At the same time, hydrogen also has anti-inflammatory, anti-apoptotic and cell signaling pathway regulating effects. As a new gaseous signaling molecule, hydrogen has attracted much attention in the field of fibrotic disease treatment due to its unique anti-inflammatory and antioxidant properties. Existing intervention strategies mostly use inhalation of hydrogen or intraperitoneal injection of hydrogen-rich saline, but it is difficult to match the actual exposure scenarios of people at high risk of pneumoconiosis (mining and manufacturing workers).

[0004] The present invention studies the application of hydrogen nano bubble water to pneumoconiosis, which has important clinical significance for exploring low-toxic and high-efficiency gas medicines or drinks for preventing and treating pneumoconiosis. Summary of the Invention

[0005] The purpose of the present invention is to provide an application of hydrogen nano bubble water in the preparation of medicines for preventing and treating pneumoconiosis.

[0006] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0007] The present invention provides application of hydrogen nano bubble water in preparing medicine for preventing and treating pneumoconiosis.

[0008] Preferably, the bubble particle size of the hydrogen nano bubble water is in the range of 100 to 200 nm.

[0009] Preferably, the hydrogen concentration of the hydrogen nanobubble water is 2000-3000 μmol / l.

[0010] Preferably, the hydrogen nanobubble water is prepared by a hydrogen nanobubble generator.

[0011] Preferably, the hydrogen nanobubble generator comes from Dalian Shuangdi Technology Co., Ltd.

[0012] Preferably, drinking hydrogen nanobubble water can effectively reduce silica-induced collagen deposition in lung tissue, improve lung function, inhibit the expression of fibrosis and inflammatory factors, and significantly improve lung function failure.

[0013] The present invention also provides a pharmaceutical composition for preventing and treating pneumoconiosis, comprising hydrogen nanobubble water and auxiliary materials.

[0014] Preferably, the dosage form of the pharmaceutical composition is a solution, injection, suspension, oral solution, emulsion or inhalation aerosol.

[0015] The present invention also provides the use of hydrogen nano bubble water in preparing a drink for improving pneumoconiosis.

[0016] Compared with the prior art, the present invention has the following beneficial effects:

[0017] Hydrogen-rich water (HRW), one of the primary carriers of hydrogen therapy, possesses both the biological properties and unique application characteristics of hydrogen therapy. However, gaseous hydrogen molecules readily dissipate in aqueous media. To address this technical bottleneck, this study utilized a nanobubble generator developed by Shuangdi. Based on the principle of hydrodynamic cavitation cutting, hydrogen nanobubble water (HNW) contains a large number of nanoscale microbubbles encapsulating hydrogen molecules. These nanobubbles undergo Brownian motion within the water, effectively slowing the escape of hydrogen into the air and increasing its bioavailability within the body. Furthermore, the portability and accessibility of HNW meet the practical needs of occupationally exposed populations.

[0018] This study explores the preventive and therapeutic effects of hydrogen nanobubble water on pneumoconiosis, demonstrating that drinking hydrogen nanobubble water effectively reduces silica-induced collagen deposition in mouse lung tissue, improves lung function, inhibits the expression of fibrosis and inflammatory factors, and significantly improves lung failure. This study provides important theoretical support for the development of safe and effective new treatment options, and has significant guiding value for the clinical treatment of pneumoconiosis. This research will provide new therapeutic approaches and clinical diagnostic markers for the clinical treatment of pneumoconiosis, and lay the theoretical and experimental foundation for the development of innovative drugs with independent intellectual property rights. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for use in the embodiments or the description of the prior art. Obviously, the drawings described below are merely embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the provided drawings without paying any creative work.

[0020] Figure 1 Statistical graph of hydrogen concentration in HNW and HRW groups.

[0021] Figure 2 Masson trichrome staining of mouse lung tissue (upper panel) and collagen volume fraction statistics (lower panel).

[0022] Figure 3 Lung function tests for mice include dynamic lung compliance (Cdyn), forced vital capacity (FVC), inspiratory capacity (IC), and forced expiratory volume in 100 milliseconds (FEV100).

[0023] Figure 4 The mRNA expression levels of fibrosis-related genes TGF-β, α-SMA and collagen I in the Control group, Silica group and Si+HNW group.

[0024] Figure 5 Figure 3 is the mRNA expression level of inflammation-related genes in the Control group, Silica group, and Si+HNW group. qRT-PCR was used to detect the mRNA levels of IL-6, IL-1β, and TNF-α. DETAILED DESCRIPTION

[0025] The present invention provides application of hydrogen nano bubble water in preparing medicine for preventing and treating pneumoconiosis.

[0026] In the present invention, the bubble particle size of the hydrogen nano bubble water is in the range of 100 to 200 nm; preferably 110 to 180 nm; more preferably 115 to 160 nm; and even more preferably 120 nm.

[0027] In the present invention, the hydrogen concentration of the hydrogen nanobubble water is 2000-3000 μmol / l, preferably 2200-2800 μmol / l, more preferably 2400-2600 μmol / l, and even more preferably 2500 μmol / l.

[0028] In the present invention, the hydrogen nano bubble water is prepared by a hydrogen nano bubble generator.

[0029] In the present invention, the hydrogen nanobubble generator comes from Dalian Shuangdi Technology Co., Ltd.

[0030] In the present invention, drinking hydrogen nanobubble water can effectively reduce silica-induced collagen deposition in lung tissue, improve lung function, inhibit the expression of fibrosis and inflammatory factors, and significantly improve lung function failure.

[0031] The present invention also provides a pharmaceutical composition for preventing and treating pneumoconiosis, comprising hydrogen nanobubble water and auxiliary materials.

[0032] In the present invention, the dosage form of the pharmaceutical composition is a solution, injection, suspension, oral liquid, emulsion or inhalation aerosol; preferably an oral liquid.

[0033] The present invention also provides the use of hydrogen nano bubble water in preparing a drink for improving pneumoconiosis.

[0034] The technical solutions provided by the present invention are described in detail below with reference to the embodiments, but they should not be construed as limiting the scope of protection of the present invention.

[0035] Example 1

[0036] The purpose of this experiment is to investigate the hydrogen concentration half-life of hydrogen nanobubble water (HNW) and hydrogen-rich water (HRW).

[0037] Hydrogen-rich water is prepared by Shuangdi Zhishui's micro hydrogen-rich water maker, and the preparation time is 10 minutes; hydrogen nano-bubble water uses the nano-bubble generator developed by Shuangdi Company (both from Dalian Shuangdi Technology Co., Ltd.). During preparation, water production is started until the pressure in the water tank reaches 0.34MPa, then the pressure is maintained for 10 minutes and then slowly released. The water is taken after the pressure is balanced to atmospheric pressure.

[0038] The Unisense micro hydrogen electrode was used to detect the time-dependent hydrogen concentration of hydrogen nanobubble water (HNW, with an average bubble size of 120 nm) and hydrogen-rich water (HRW). It was found that the hydrogen molecule concentration of the two types of hydrogen-rich water just prepared was about 2700 μmol / l. As time passed, it was found that the hydrogen escape rate in hydrogen-rich water was significantly faster than that in hydrogen nanobubble water. It was also found that the hydrogen half-life of hydrogen-rich water was 6 hours, while the hydrogen concentration half-life in hydrogen nanobubble water was 12 hours ( Figure 1 ).

[0039] Example 2

[0040] In vivo mouse experiments: 24 8-week-old male C57BL / 6 mice were randomly divided into 3 groups:

[0041] (1) Control group: After freely drinking triple-distilled water for 7 days, 50 μl of normal saline was instilled into the oropharynx once, and then the subjects continued to drink triple-distilled water freely for 28 days;

[0042] (2) Silicosis model group (Silica): Silicosis was induced by a single oropharyngeal instillation of 50 μl of silica suspension (5 mg / rat) for 28 days, during which the rats were free to drink triple-distilled water;

[0043] (3) Hydrogen nanobubble water treatment group (Si+HNW): After allowing mice to freely drink hydrogen nanobubble water for 7 days in advance, 50 μl of silica suspension (5 mg / mouse) was orally instilled to induce silicosis modeling. After that, mice were allowed to freely drink HNW for 28 days, and new HNW was replaced every 12 hours to ensure the hydrogen content in the HNW.

[0044] After the experiment, the mice underwent pulmonary function tests, and lung tissue was collected for Masson trichrome staining. Real-time fluorescence quantitative qRT-PCR was used to detect the mRNA expression levels of collagen I, TGF-β, IL-6, IL-1β, and GAPDH in the mouse lung tissue.

[0045] The results are as follows Figures 2 to 5 shown. Figure 2 This is a Masson trichrome stain of mouse lung tissue. In silicotic mice, drinking hydrogen nanobubble water reduced silica-induced collagen deposition. Masson staining was used to observe collagen deposition in lung tissue. Compared with the control group, the silica group showed more severe collagen deposition and inflammatory cell infiltration. However, drinking hydrogen nanobubble water reduced both collagen deposition and inflammatory cell infiltration.

[0046] Figure 3 Lung function tests for mice included dynamic lung compliance (Cdyn), forced vital capacity (FVC), inspiratory capacity (IC), and forced expiratory volume in 100 milliseconds (FEV100). Compared with the control group, Cdyn, FVC, IC, and FVC100 values ​​were significantly decreased in the treated group (p<0.05), indicating that overall lung function in the experimental group was suppressed. Lung function improved in mice that drank hydrogen nanobubble water, reflecting the recovery of lung tissue elasticity and respiratory function.

[0047] Figure 4Figure 3. Fibrosis-related gene mRNA expression levels of TGF-β, α-SMA, and collagen I in the control, silica, and Si+HNW groups. qRT-PCR analysis of TGF-β, α-SMA, and collagen I mRNA levels revealed that the silica group significantly increased their expression, while administration of hydrogen nanobubble water downregulated their expression. (*Compared with the silica group, p < 0.05).

[0048] Figure 5 Figure 2 shows the mRNA expression levels of inflammation-related genes in the control, Silica, and Si+HNW groups. qRT-PCR analysis of IL-6, IL-1β, and TNF-α mRNA levels revealed that the Silica group significantly increased the expression of these genes, while administration of hydrogen nanobubble water downregulated their expression. (*Compared to the Silica group, p < 0.05).

[0049] This study explores the preventive and therapeutic effects of hydrogen nanobubble water on pneumoconiosis, demonstrating that drinking hydrogen nanobubble water effectively reduces silica-induced collagen deposition in mouse lung tissue, improves lung function, inhibits the expression of fibrosis and inflammatory factors, and significantly improves lung failure. This study provides important theoretical support for the development of safe and effective new treatment options, and has significant guiding value for the clinical treatment of pneumoconiosis. This research will provide new therapeutic approaches and clinical diagnostic markers for the clinical treatment of pneumoconiosis, and lay the theoretical and experimental foundation for the development of innovative drugs with independent intellectual property rights.

[0050] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as within the scope of protection of the present invention.

Claims

1. Application of hydrogen nanobubble water in the preparation of drugs for the prevention and treatment of pneumoconiosis.

2. The use according to claim 1, characterized in that The bubble particle size of the hydrogen nano bubble water is in the range of 100 to 200 nm.

3. The use according to claim 1, characterized in that The hydrogen concentration of the hydrogen nano bubble water is 2000-3000 μmol / l.

4. The use according to claim 1, characterized in that The hydrogen nano bubble water is prepared by a hydrogen nano bubble generator.

5. The use according to claim 4, characterized in that The hydrogen nanobubble generator comes from Dalian Shuangdi Technology Co., Ltd.

6. The use according to claim 1, characterized in that Drinking hydrogen nanobubble water can effectively reduce silica-induced collagen deposition in lung tissue, improve lung function, inhibit the expression of fibrosis and inflammatory factors, and significantly improve lung function failure.

7. A pharmaceutical composition for preventing and treating pneumoconiosis, characterized in that: Including hydrogen nano bubble water and auxiliary materials.

8. The pharmaceutical composition according to claim 7, characterized in that The dosage form of the pharmaceutical composition is solution, injection, suspension, oral solution, emulsion or inhalation aerosol.

9. Application of hydrogen nanobubble water in the preparation of beverages for improving pneumoconiosis.

Images